Copyright Reports & Markets. All rights reserved.

Global Nanocarrier-Based Vaccine Market Growth (Status and Outlook) 2021-2026

Request for Sample of this report
Buy now

1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global Nanocarrier-Based Vaccine Market Size 2016-2026
    • 2.1.2 Nanocarrier-Based Vaccine Market Size CAGR by Region 2020 VS 2021 VS 2026
  • 2.2 Nanocarrier-Based Vaccine Segment by Type
    • 2.2.1 Adjuvants
    • 2.2.2 Adjuvants
  • 2.3 Nanocarrier-Based Vaccine Market Size by Type
    • 2.3.1 Global Nanocarrier-Based Vaccine Market Size CAGR by Type
    • 2.3.2 Global Nanocarrier-Based Vaccine Market Size Market Share by Type (2016-2021)
  • 2.4 Nanocarrier-Based Vaccine Segment by Application
    • 2.4.1 Hospital
    • 2.4.2 Clinic
    • 2.4.3 Other
  • 2.5 Nanocarrier-Based Vaccine Market Size by Application
    • 2.5.1 Global Nanocarrier-Based Vaccine Market Size CAGR by Application
    • 2.5.2 Global Nanocarrier-Based Vaccine Market Size Market Share by Application (2016-2021)

3 Nanocarrier-Based Vaccine Market Size by Players

  • 3.1 Nanocarrier-Based Vaccine Market Size Market Share by Players
    • 3.1.1 Global Nanocarrier-Based Vaccine Revenue by Players (2019-2021E)
    • 3.1.2 Global Nanocarrier-Based Vaccine Revenue Market Share by Players (2019-2021E)
  • 3.2 Global Nanocarrier-Based Vaccine Key Players Head office and Products Offered
  • 3.3 Market Concentration Rate Analysis
    • 3.3.1 Competition Landscape Analysis
    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2019-2021E)
  • 3.4 New Products and Potential Entrants
  • 3.5 Mergers & Acquisitions, Expansion

4 Nanocarrier-Based Vaccine by Regions

  • 4.1 Nanocarrier-Based Vaccine Market Size by Regions (2016-2021)
  • 4.2 Americas Nanocarrier-Based Vaccine Market Size Growth (2016-2021)
  • 4.3 APAC Nanocarrier-Based Vaccine Market Size Growth (2016-2021)
  • 4.4 Europe Nanocarrier-Based Vaccine Market Size Growth (2016-2021)
  • 4.5 Middle East & Africa Nanocarrier-Based Vaccine Market Size Growth (2016-2021)

5 Americas

  • 5.1 Americas Nanocarrier-Based Vaccine Market Size by Country (2016-2021)
  • 5.2 Americas Nanocarrier-Based Vaccine Market Size by Type (2016-2021)
  • 5.3 Americas Nanocarrier-Based Vaccine Market Size by Application (2016-2021)
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC Nanocarrier-Based Vaccine Market Size by Region (2016-2021)
  • 6.2 APAC Nanocarrier-Based Vaccine Market Size by Type (2016-2021)
  • 6.3 APAC Nanocarrier-Based Vaccine Market Size by Application (2016-2021)
  • 6.4 China
  • 6.5 Japan
  • 6.6 Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia

7 Europe

  • 7.1 Europe Nanocarrier-Based Vaccine by Country (2016-2021)
  • 7.2 Europe Nanocarrier-Based Vaccine Market Size by Type (2016-2021)
  • 7.3 Europe Nanocarrier-Based Vaccine Market Size by Application (2016-2021)
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa Nanocarrier-Based Vaccine by Region (2016-2021)
  • 8.2 Middle East & Africa Nanocarrier-Based Vaccine Market Size by Type (2016-2021)
  • 8.3 Middle East & Africa Nanocarrier-Based Vaccine Market Size by Application (2016-2021)
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers and Impact
    • 9.1.1 Growing Demand from Key Regions
    • 9.1.2 Growing Demand from Key Applications and Potential Industries
  • 9.2 Market Challenges and Impact
  • 9.3 Market Trends

10 Global Nanocarrier-Based Vaccine Market Forecast

  • 10.1 Global Nanocarrier-Based Vaccine Forecast by Regions (2021-2026)
    • 10.1.1 Global Nanocarrier-Based Vaccine Forecast by Regions (2021-2026)
    • 10.1.2 Americas Nanocarrier-Based Vaccine Forecast
    • 10.1.3 APAC Nanocarrier-Based Vaccine Forecast
    • 10.1.4 Europe Nanocarrier-Based Vaccine Forecast
    • 10.1.5 Middle East & Africa Nanocarrier-Based Vaccine Forecast
  • 10.2 Americas Nanocarrier-Based Vaccine Forecast by Countries (2021-2026)
    • 10.2.1 United States Nanocarrier-Based Vaccine Market Forecast
    • 10.2.2 Canada Nanocarrier-Based Vaccine Market Forecast
    • 10.2.3 Mexico Nanocarrier-Based Vaccine Market Forecast
    • 10.2.4 Brazil Nanocarrier-Based Vaccine Market Forecast
  • 10.3 APAC Nanocarrier-Based Vaccine Forecast by Region (2021-2026)
    • 10.3.1 China Nanocarrier-Based Vaccine Market Forecast
    • 10.3.2 Japan Nanocarrier-Based Vaccine Market Forecast
    • 10.3.3 Korea Nanocarrier-Based Vaccine Market Forecast
    • 10.3.4 Southeast Asia Nanocarrier-Based Vaccine Market Forecast
    • 10.3.5 India Nanocarrier-Based Vaccine Market Forecast
    • 10.3.6 Australia Nanocarrier-Based Vaccine Market Forecast
  • 10.4 Europe Nanocarrier-Based Vaccine Forecast by Country (2021-2026)
    • 10.4.1 Germany Nanocarrier-Based Vaccine Market Forecast
    • 10.4.2 France Nanocarrier-Based Vaccine Market Forecast
    • 10.4.3 UK Nanocarrier-Based Vaccine Market Forecast
    • 10.4.4 Italy Nanocarrier-Based Vaccine Market Forecast
    • 10.4.5 Russia Nanocarrier-Based Vaccine Market Forecast
  • 10.5 Middle East & Africa Nanocarrier-Based Vaccine Forecast by Region (2021-2026)
    • 10.5.1 Egypt Nanocarrier-Based Vaccine Market Forecast
    • 10.5.2 South Africa Nanocarrier-Based Vaccine Market Forecast
    • 10.5.3 Israel Nanocarrier-Based Vaccine Market Forecast
    • 10.5.4 Turkey Nanocarrier-Based Vaccine Market Forecast
    • 10.5.5 GCC Countries Nanocarrier-Based Vaccine Market Forecast
  • 10.6 Global Nanocarrier-Based Vaccine Forecast by Type (2021-2026)
  • 10.7 Global Nanocarrier-Based Vaccine Forecast by Application (2021-2026)

11 Key Players Analysis

  • 11.1 Emergent BioSolutions
    • 11.1.1 Emergent BioSolutions Company Information
    • 11.1.2 Emergent BioSolutions Nanocarrier-Based Vaccine Product Offered
    • 11.1.3 Emergent BioSolutions Nanocarrier-Based Vaccine Revenue, Gross Margin and Market Share (2019-2021)
    • 11.1.4 Emergent BioSolutions Main Business Overview
    • 11.1.5 Emergent BioSolutions Latest Developments
  • 11.2 Sanofi
    • 11.2.1 Sanofi Company Information
    • 11.2.2 Sanofi Nanocarrier-Based Vaccine Product Offered
    • 11.2.3 Sanofi Nanocarrier-Based Vaccine Revenue, Gross Margin and Market Share (2019-2021)
    • 11.2.4 Sanofi Main Business Overview
    • 11.2.5 Sanofi Latest Developments
  • 11.3 GlaxoSmithKline Biologicals
    • 11.3.1 GlaxoSmithKline Biologicals Company Information
    • 11.3.2 GlaxoSmithKline Biologicals Nanocarrier-Based Vaccine Product Offered
    • 11.3.3 GlaxoSmithKline Biologicals Nanocarrier-Based Vaccine Revenue, Gross Margin and Market Share (2019-2021)
    • 11.3.4 GlaxoSmithKline Biologicals Main Business Overview
    • 11.3.5 GlaxoSmithKline Biologicals Latest Developments
  • 11.4 Merck
    • 11.4.1 Merck Company Information
    • 11.4.2 Merck Nanocarrier-Based Vaccine Product Offered
    • 11.4.3 Merck Nanocarrier-Based Vaccine Revenue, Gross Margin and Market Share (2019-2021)
    • 11.4.4 Merck Main Business Overview
    • 11.4.5 Merck Latest Developments
  • 11.5 Pfizer
    • 11.5.1 Pfizer Company Information
    • 11.5.2 Pfizer Nanocarrier-Based Vaccine Product Offered
    • 11.5.3 Pfizer Nanocarrier-Based Vaccine Revenue, Gross Margin and Market Share (2019-2021)
    • 11.5.4 Pfizer Main Business Overview
    • 11.5.5 Pfizer Latest Developments
  • 11.6 Novartis
    • 11.6.1 Novartis Company Information
    • 11.6.2 Novartis Nanocarrier-Based Vaccine Product Offered
    • 11.6.3 Novartis Nanocarrier-Based Vaccine Revenue, Gross Margin and Market Share (2019-2021)
    • 11.6.4 Novartis Main Business Overview
    • 11.6.5 Novartis Latest Developments
  • 11.7 Moderna
    • 11.7.1 Moderna Company Information
    • 11.7.2 Moderna Nanocarrier-Based Vaccine Product Offered
    • 11.7.3 Moderna Nanocarrier-Based Vaccine Revenue, Gross Margin and Market Share (2019-2021)
    • 11.7.4 Moderna Main Business Overview
    • 11.7.5 Moderna Latest Developments

12 Research Findings and Conclusion

According to this latest study, the 2021 growth of Nanocarrier-Based Vaccine will have significant change from previous year. By the most conservative estimates of global Nanocarrier-Based Vaccine market size (most likely outcome) will be a year-over-year revenue growth rate of % in 2021, from US$ million in 2020. Over the next five years the Nanocarrier-Based Vaccine market will register a % CAGR in terms of revenue, the global market size will reach US$ million by 2026.

This report presents a comprehensive overview, market shares, and growth opportunities of Nanocarrier-Based Vaccine market by product type, application, key players and key regions and countries.

Segmentation by type: breakdown data from 2016 to 2021 in Section 2.3; and forecast to 2026 in section 10.7.
Adjuvants
Delivery Systems

Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 10.8.
Hospital
Clinic
Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
Emergent BioSolutions
Sanofi
GlaxoSmithKline Biologicals
Merck
Pfizer
Novartis
Moderna
Buy now